What is the recommended management of duodenal ulcer, including H. pylori eradication therapy, PPI duration, and handling of complications?

Management of Duodenal Ulcers

For duodenal ulcers, initiate H. pylori testing immediately and treat with 14-day bismuth quadruple therapy or concomitant (non-bismuth) quadruple therapy as first-line eradication, followed by confirmation of eradication 4-6 weeks post-treatment. 1, 2

H. Pylori Eradication - First-Line Therapy

The choice of first-line regimen depends on local antibiotic resistance patterns and bismuth availability:

Preferred Regimens (14 days duration):

Bismuth Quadruple Therapy (PBMT):

• PPI twice daily + Bismuth (4 times daily) + Metronidazole 400-500 mg (3-4 times daily) + Tetracycline 500 mg (4 times daily)
• This is the most robust option, particularly effective even with metronidazole resistance and in areas of high dual clarithromycin-metronidazole resistance 1, 2

Concomitant Non-Bismuth Quadruple Therapy (PAMC):

• PPI twice daily + Amoxicillin 1000 mg twice daily + Metronidazole 500 mg twice daily + Clarithromycin 500 mg twice daily
• Appropriate when bismuth is unavailable in areas of high clarithromycin resistance 1

Critical Duration Point:

All three major consensus groups (Toronto, Maastricht V/Florence, ACG) agree that 14 days is superior to shorter durations for first-line therapy, with the principle that succeeding on the first attempt is paramount to avoid retreatment, retesting, and microbiota disruption 1.

Regimens to Avoid as First-Line:

• PPI triple therapy (PPI + clarithromycin + amoxicillin) is now restricted due to increasing clarithromycin resistance, achieving only ~70% eradication rates 1, 3
• Sequential and hybrid therapies are considered non-ideal options 1

PPI Duration for Duodenal Ulcers

For uncomplicated duodenal ulcers, 1 week of triple therapy is sufficient for ulcer healing without additional PPI monotherapy 4. However, this applies only to uncomplicated cases.

For bleeding duodenal ulcers with high-risk stigmata after successful endoscopic therapy:

• IV PPI loading dose followed by continuous IV infusion for 3 days 5
• Then switch to twice-daily oral PPI for 14 days, followed by once-daily 5
• After completing eradication therapy, continue single daily-dose oral PPI only as dictated by underlying cause 5

Important caveat: Prolonging PPI therapy after effective H. pylori eradication is unnecessary for duodenal ulcers (unlike gastric ulcers which require 3 additional weeks) 6, 7.

Confirmation of Eradication

Universal test-of-cure is mandatory 4-6 weeks after completing therapy using:

• 13C-urea breath test (preferred), OR
• Stool antigen test 5, 4, 8

Critical pitfall: Negative H. pylori tests obtained during acute bleeding should be repeated, as false negatives are common in the acute setting 5.

Salvage Therapy for Treatment Failure

If first-line therapy fails and antibiotic susceptibility is unknown:

• "Optimized" bismuth quadruple therapy for 14 days (if not previously used) 2
• Rifabutin triple therapy (PPI + Amoxicillin 1000 mg twice daily + Rifabutin 150 mg twice daily) for 10-14 days 1, 2

Avoid clarithromycin or levofloxacin-containing salvage regimens unless antibiotic susceptibility is confirmed 2.

High-dose dual therapy (Rabeprazole 20 mg four times daily + Amoxicillin 750 mg four times daily) is considered an option by all consensus groups as rescue therapy 1.

Management of Complications

Bleeding Ulcers:

• Endoscopic therapy is first-line for high-risk stigmata 5
• Most patients require hospitalization for at least 72 hours after endoscopic hemostasis 5
• If endoscopic therapy fails: seek surgical consultation or consider percutaneous embolization where available 5
• Patients at low risk after endoscopy can be fed within 24 hours 5

Perforation and Stenosis:

Conservative therapy may be considered, though surgical consultation is often needed 9.

Special Considerations for NSAID/Antiplatelet Users

If duodenal ulcer occurs in NSAID users:

• Discontinue NSAID if possible and treat with PPI 9
• If NSAID cannot be discontinued, continue PPI therapy 9

For patients with previous ulcer bleeding requiring antiplatelet therapy:

• Restart aspirin as soon as cardiovascular risk outweighs bleeding risk 5
• Use PPI co-therapy with single or dual antiplatelet agents 5
• Use PPI co-therapy with anticoagulants (warfarin or DOACs) 5

For prevention in patients with ulcer history:

• NSAID users: PPIs with or without celecoxib, or vonoprazan 9
• Low-dose aspirin users: PPIs or vonoprazan 9

The combination of H. pylori infection and NSAID use synergistically increases bleeding risk more than sixfold, making eradication particularly important in NSAID users 8.